Novel drugs for chronic lymphoid leukemias: Mechanism of action and therapeutic activity

Current Medicinal Chemistry

Volumn 16, Issue 18, 2009, Pages 2212-2234

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Bryostatin 1; CLL; Flavopiridol; HCL; Lenalidomide; Monoclonal antibodies; Oblimersen; Prolymphocytic leukemia; Purine nucleoside ananalogs

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 HYDROXYCYCLOPHOSPHAMIDE; ABT 263; AG LY 317615; ANTINEOPLASTIC AGENT; BORTEZOMIB; BRYOSTATIN 1; CLOFARABINE; CLORAL; CYCLOPHOSPHAMIDE; DEFOROLIMUS; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; FLAVOPIRIDOL; FLUDARABINE; FORODESINE; GLIVEK; HUMAX CD 4; IMATINIB; ISOSORBIDE; MDL 107826A; MK 8669; NELARABINE; NSC 701852; OBATOCLAX; OBLIMERSEN; R ROSCOVITINE; RAPAMYCIN; RITUXIMAB; ROMIDEPSIN; ROSCOVITINE; TEMSIROLIMUS; THALIDOMIDE; TW 37; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZANOLIMUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; CREATININE BLOOD LEVEL; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DECREASED APPETITE; DIARRHEA; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; EUPHORIA; FATIGUE; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; GLIOBLASTOMA; HAIRY CELL LEUKEMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; ILEUS; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LIVER FUNCTION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOID METAPLASIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOMNOLENCE; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; UPREGULATION; VOMITING; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG SCREENING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR STRUCTURE;

EID: 67949094458     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709788453122     Document Type: Review

References (230)

1. Kroft, S.H.; Finn, W.G.; Peterson, L.C. The pathology of chronic lymphoid leukemia. Blood Rev., 1995, 9, 234-50
2. Ravandi, F.; O'Brien, S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: Diagnosis and treatment. Mayo Clin. Proc., 2005, 80, 1660-74.
3. Jaffe, S.; Harris, N.; Stein, H; Vardiman, J.W. Tumours of Hematopoietic and Lymphocid Tissues. World Health Organization Classification of Tumours, 2001, Lyon, France: JARC Press.
4. Redaelli, A.; Laskin, B.L.; Redaelli, A.; Laskin, B.L.; Stephens. J.M.; Botteman, M.F.; Pashos, C.L. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care (Engl). 2004, 13, 279-87.
5. Mauro, F.R.; Foa, R. Young patients with chronic lymphocytic leukemia.In Chronic llymphocytic leukemia. Molecular genetics, biology, diagnosis, and management. Ed. G.B. Faguet. Humana Press Inc, Totova, New. Jersey, 2004, pp. 401-413.
6. Dighiero, G.; Hamblin, T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371, 1017-29.
7. Dighiero, G.; Maloum, K.; Desablens, B.; Cazin, B.; Navarro, M.; Leblay, R.; Leporrier, M.; Jaubert, J.; Lepeu, G.; Dreyfus, B.; Binet, J.L. Travade P.Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N. Engl. J. Med., 1998, 338, 1506-14.
8. Cheson, B.D.; Bennett, J.M.; Grever, M.; Kay, N.; Keating, M.J.; O'Brien, S.; Rai, K.R. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, 1996, 87, 4990-7.
9. Robak, T.; Kasznicki, M. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia, 2002, 16, 1015-27.
10. Robak, T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat. Rev., 2007, 33, 710-28
11. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threatte, G.A.; Larson, R.A.; Cheson, B.D.; Schiffer, C.A. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocyticleukemia. N. Engl. J. Med., 2000, 343, 1750-7.
12. Robak, T.; Bloński, J.Z.; Kasznicki, M.; Blasińska-Morawiec, M.; Krykowski, E.; Dmoszyńska, A.; Mrugala-Spiewak, H.; Skotnicki, A.B.; Nowak, W.; Konopka, L.; Ceglarek, B.; Maj, S.; Dwilewicz-Trojaczek, J.; Hellmann, A.; Urasiński, I.; Zdziarska, B.; Kotlarek-Haus, S.; Potoczek, S.; Grieb, P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood, 2000, 96, 2723-9.
13. Eichhorst, B..F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jäger, U.; Bergmann, M.; Stilgenbauer, S.; Schweighofer, C.; Wendtner, C.M.; Döhner, H.; Brittinger, G.; Emmerich, B.; Hallek, M. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood, 2006, 107, 885-91.
14. Flinn, I.W.; Neuberg, D.S.; Grever, M.R.; Dewald, G.W.; Bennett, J.M.; Paietta, E.M.; Hussein, M.A.; Appelbaum, F.R.; Larson, R.A.; Moore, D. Jr, Tallman, M.S. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol., 2007, 25, 793-98.
15. Catovsky, D.; Richards S,; Matutes, E.; Oscier, D.: M.J. Bezares R.F.; Pettit, A.R.; Hamblin, T.; Miligan D.W.; Child,J.A.; Hamilton, M.S.; Dearden, C.E.; Smith, A.G.; Bosanquet, A.G.; Davis Z.; Brito-Babapulle, V.; Else, M.; Wade, R.; Hillmen, P.; U.K. National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet, 2007, 370, 230-9.
16. Robak, T.; Blonski, J.Z.; Gora-Tybor, J.; Jamroziak, K.; Dwilewicz-Trojaczek, J.; Tomaszewska, A.; Konopka, L.; Ceglarek, B.; Dmoszynska, A.; Kowal, M.; Kloczko, J.; Stella-Holowiecka, B.; Sulek, K.; Calbecka, M.; Zawilska, K.; Kuliczkowski, K.; Skotnicki, A.B.; Warzocha, K.; Kasznicki, M; Polish Leukemia Group (PALG CLL2). Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). Blood, 2006, 108, 473-9.
17. O'Brien, S.M.; Kantarjian, H.; Thomas, D.A.; Giles, F.J.; Freireich, E.J.; Cortes, J.; Lerner, S.; Keating, M.J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol., 2001, 19, 2165-70.
18. Byrd, J.C.; Murphy, T.; Howard, R.S.; Lucas, M.S.; Goodrich, A.; Park, K.; Pearson, M.; Waselenko, J.K.; Ling, G.; Grever, M.R.; Grillo-Lopez, A.J.; Rosenberg, J.; Kunkel, L.; Flinn, I.W. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol., 2001, 19, 2153-64.
19. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther., 2008, 8, 1033-51.
20. Osterborg, A.; Dyer, M.J.; Bunjes, D.; Pangalis, G.A.; Bastion, Y.; Catovsky, D.; Mellstedt, H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J. Clin. Oncol., 1997, 15, 1567-74.
21. Hillmen, P.; Skotnicki, A.B.; Robak, T.; Jaksic, B.; Dmoszynska, A.; Wu, J.; Sirard, C.; Mayer, J. Alemtuzumab compared with chlorambucil as first-line therapy for patients requiring treatment for chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25, 5616-23.
22. Keating, M.J.; O'Brien, S.; Albitar, M.; Lerner, S.; Plunkett, W.; Giles, F.; Andreeff, M.; Cortes, J.; Faderl, S.; Thomas, D.; Koller, C.; Wierda, W.; Detry, M.A.; Lynn, A.; Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23, 4079-88.
23. Wierda, W.; O'Brien, S.; Wen, S.; Faderl, S.; Garcia-Manero, G.; Thomas, D, Do K.A.; Cortes, J.; Koller, C.; Beran, M.; Ferrajoli, A.; Giles, F.; Lerner, S.; Albitar, M.; Kantarjian, H.; Keating. M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23, 4070-8
24. Kay, N.E.; Geyer, S.M.; Call, T.G.; Shanafelt, T.D.; Zent, C.S.; Jelinek, D.F.; Tschumper, R.; Bone, N.D.; Dewald, G.W.; Lin, T.S.; Heerema, N.A.; Smith, L.; Grever, M.R.; Byrd, J.C. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood, 2007, 109, 405-11.
25. Robak, T.; Smolewski, P.; Cebula, B.; Grzybowska-Izydorczyk, O.; Blonski, J.Z. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. Eur. J. Haematol., 2007, 79, 107-13.
26. Pettitt, A.R.; Zuzel, M.; Cawley, J.C. Hairy cell leukaemia: Biology and management. Br. J. Haematol., 1999, 106, 2-8.
27. Mey, U.; Schmidt-Wolf, I. Advances in the treatment of hairy trehl, J.; Gorschlüter, M.; Ziske, C.; Glasmacher, A.; Pralle, H.; Hairy-cell leukaemia. Lancet Oncol., 2003, 4, 86-94.
28. Staines, A.; Cartwright, R.A. Hairy cell leukaemia: Descriptive epidemiology and a case control study. Br. J. Haematol., 1993, 85, 714-7.
29. Bernstein, L.; Newton, P.; Ross, R.K. Epidemiology of hairy cell leukemia: An update. Curr. Opin. Hematol., 2003, 10, 258-66.
30. Robak, T. Current treatment options in hairy cell leukemia and hairy cell leukemia variant. Cancer Treat. Rev.,. 2006, 32, 365-76.
31. Robak, T.; Jamroziak, K.; Gora-Tybor, J.; Blonski, J.Z.; Kasznicki, M.; Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska, B.; Calbecka, M.; Kostyra, A.; Hellmann, A.; Lewandowski, K.; Stella-Holowiecka, B.; Sulek, K.; Gawronski, K.; Skotnicki, A.B.; Nowak, W.; Zawilska, K.; Molendowicz-Portala, L.; Kloczko, J.; Sokolowski, J.; Warzocha, K.; Seferynska, I.; Ceglarek, B.; Konopka, L. Cladribine weekly versus daily schedule for untreated hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized multicenter trial. Blood, 2007, 109, 3672-5.
32. Absi, A.; Hsi, E.; Kulaycio, M. Prolymphocytic leukemia. Curr Treat Options Oncol., 2005, 6, 197-208.
33. Krishnan, B.; Matutes, E.; Dearden, C. Prolymphocytic leukemias. Semin. Oncol., 2006, 33, 257-63.
34. Robak, T.; Robak, P. Current treatment options in prolymphocytic leukemia. Med. Sci. Monit., 2007, 13, RA 69-80
35. Kantarjian, H.M.; Childs, C.; O'Brien, S.; Huh, Y.; Beran, M.; Schachner, J.; Koller, C.; Keating, M.J. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med., 1991, 90, 223-8.
36. Saven, A.; Lee, T.; Schlutz, M.; Jacobs, A.; Ellison, D.; Longmire, R.; Piro, L. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J. Clin. Oncol., 1997, 15, 37-43.
37. Mercieca, J.; Matutes, E.; Dearden, C.; MacLennan, K.; Catovsky, D. The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol., 1994, 12, 2588-93.
38. Pawson, R.; Dyer, M.J.; Barge, R.; Matutes, E.; Thornton, P.D.; Emmett, E.; Kluin-Nelemans, J.C.; Fibbe, W.E.; Willemze, R.; Catovsky, D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol., 1997, 15, 2667-72.
39. Wlodarski, M.W.; Schade, A.E.; MaciejewskI, J.P. T-large granular lymphocyte leukemia: Current molecular concepts. Hematology, 2006, 11, 245-6.
40. Alekshun, T.J.; SokoL, L. Diseases of large granular lymphocytes. Cancer Control., 2007, 14, 141-50.
41. Lamy, T.; Loughran, T.P. Clinical features of large granular lymphocyte leukemia. Semin. Hematol., 2003, 40, 185-95.
42. Sokol, L.; Loughran, T.P.Ir: Large granular lymphocyte leukemia: Oncologist, 2006, 11, 263-73.
43. Yasunaga, J.; Matsuoku, M. Human T-cell leukemia virus type I induces adult T-cell leukemia: From clinical aspects to molecular mechanisms. Cancer Control., 2007, 14, 133-40.
44. Foucar, K. Mature T-cell leukemia including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma and Sezary syndrome. Am. J. Clin. Pathol., 2007, 127, 496-510.
45. Yamada Y, Tomonoga M: The current status of therapy for adult T-cell leukemia - lymphoma in Japan. Leuk. Lymphoma, 2003, 44, 611-8.
46. Robak, T.; Lech-Maranda, E.; Korycka, A.; Robak, E. Purine nucleoside analogs as immunosuppressive ans antineoplastic agents: Mechanism of action and clinical activity. Curr. Med. Chem., 2006, 13, 3165-89.
47. Lech-Maranda, E.; Korycka, A.; Robak, T. Pharmacological and clinical studies on purine nucleoside analogs-new antocancer agents. Mini Rev. Med. Chem., 2006, 6, 575-81.
48. Larson, R.A. Three new drugs for acute lymphoblastic leukemia nelarabine, clofarabine, and forodesine. Semin. Oncol., 2007, 34 (Suppl 5), 13-20.
49. Szafraniec, S.I.; Stachnik, K.J.; Skierski, J.S. New nucleoside analogs in the treatment of hematological disorders. Acta Pol. Pharm., 2004, 61, 223-32.
50. Jeha, S.; Gandhi, V.; Chan, K.W.; McDonald, L.; Ramirez, I.; Madden, R.; Rytting,M.; Brandt, M.; Keating, M.; Plunkett, W.; Kantarjian, H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 2004, 103, 784-9
51. Kisor, D.F.; Plunkett, W.; Kurtzberg, J.; Mitchell, B.; Hodge, J.P.; Ernst, T.; Keating, M.J.; Gandhi, V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol., 2000, 18, 995-1003.
52. Korycka, A.; Błoński, J.Z.; Robak, T. Forodesine (BCX-1777, Immucillin H)-a new purine nucleoside analogue: Mechanism of action and potential clinical application. Mini Rev. Med. Chem., 2007, 7, 976-83.
53. Bantia, S.; Kilpatrick, J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Curr. Opin. Drug. Discov. Devel., 2004, 7, 243-247.
54. PuiBonate, P.L.; Arthaud, L.; Cantrell, W.R. Jr.; Stephenson, K.; Secrist III, J.A.; Weitman, S. Nat. Rev. Drug. Disc., 2006, 5, 855-863.
55. Van den Neste, E.; Cardoen, S.; Offner, F.; Bontemps, F. Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: Fludarabine and cladribine (review). Int. J. Oncol., 2005, 27, 1113-24.
56. Pettitt, A.R. Mechanism of action of purine analogues in chronic lymphocytic leukaemia. Br. J. Haematol., 2003, 121, 692-702.
57. Gandhi, V.; Plunkett, W.; Bonate, P.L.; Du, M.; Nowak, B.; Lerner, S.; Keating, M.J. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: Strategy for treatment. Clin. Cancer. Res., 2006, 12, 4011-17.
58. Kantarjian, H.M.; Jeha, S.; Ganhi, V.; Wess, M.; Faderl, S. Clofarabine: past present and future. Leuk. Lymphoma, 2007, 48, 1922-30.
59. Roecker, A.M.; Allison, J.C.; Kisor, D.F. Nelarabine: Efficacy in the treatment of clinical malignancies. Future Oncol., 2006, 2, 441-8.
60. Rodriguez, C.O.Jr.; Mitchell, B.S.; Ayres, M.; Eriksson. S.; Gandhi, V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res., 2002, 62, 3100-5.
61. Kisor DF. Nelarabine use in leukemias. Drugs Today, 2006, 42, 455-65.
62. Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood, 2003, 102, 1842-8.
63. Kurtzberg, J.; Ernst, T.J.; Keating. M.J.; Gandhi, V.; Hodge, J.P.; Kisor, D.F.; Lager, J.J.; Stephens, C.; Levin, J.; Krenitsky, T.; Elion, G.; Mitchell, B.S. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol., 2005, 23, 3396-403.
64. Berg, S.L.; Blaney, S.M.; Devidas, M.; Lampkin, T.A.; Murgo, A.; Bernstein, M.; Billett, A.; Kurtzberg, J.; Reaman, G.; Gaynon, P.; Whitlock, J.; Krailo, M.; Harris, M.B; Children's Oncology Group. Phase II study of nelarabine (compound 506 U78) in children and young adults with refractory T-cell malignancies: A report from Children's Oncology Group. J. Clin. Oncol., 2005, 23, 3376-82.
65. Cohen, M.H.; Johnson, J.R.; Justice, R.; Pazdu, R. FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist, 2008, 13, 709-14
66. Evans, G.B.; Furneaux, R.H.; Lewandowicz, A.; Schramm, V.L.; Tyler, P.C. Synthesis of second-generation transition state analogues of human purine nucleoside phosphorylase. J. Med. Chem., 2003, 46, 5271-6.
67. Clinch, K.; Evans, G.B.; Fleet, G.W.; Furneaux, R.H.; Johnson, S.W.; Lenz, D.H.; Mee, S.P.; Rands, P.R.; Schramm, V.L.; Taylor Ringia, E.A.; Tyler, P.C. Synthesis and bio-activities of Lenantiomers of two potent transition state analogue inhibitor of purine nucleoside phosphorylases. Org. Biomol. Chem., 2006, 4, 1131-1139.
68. Gandhi, V.; Balakrishnan, K. Pharmacology and mechanism of action of forodesine, a T-cell target agent. Semin Oncol., 2007, 34, (Suppl. 5), 8-12.
69. Plunkett, W.; Saunders, P.P. Metabolism and action of purine nucleoside analogs. Pharmacol. Ther., 1991, 49, 239-68.
70. Balakrishnan, K.; Nimmanapalli, R.; Ravandi, F.; Keating, M.J.; Gandhi, V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 2006, 108, 2392-8.
71. Galmarini, C.M. Drug evaluation: Forodesine - PNP inhibitor for the treatment of leukemia, lymphoma and solid tumor. Drugs, 2006, 9, 712-22.
72. Gandhi, V.; Kilpatrick, J.M.; Plunkett, W.; Ayres, M.; Harman, L.; Du M, Bantia, S.; Davisson, J.; Wierda, W.G.; Faderl, S.; Kantarjian, H.; Thomas, D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood, 2005, 106, 4253-60.
73. Chanan-Khan A. Bcl-2 antisense therapy in B-cell malignancies. Blood Rev., 2005, 19, 213-221.
74. Cheson, B.D. Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Therap. Clin. Risk- Man, 2007, 3, 855-70.
75. Klasa, R.J.; Gillum, A.M.; Klem, R.E.; Frankel, S.R. Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment. Antisense Nucleic. Acid Drug Dev., 2002, 12, 193-213.
76. O'Brien, S.M.; Cunningham, C.C.; Golenkov, A.K.; Turkina, A.G.; Novick, S.C. Rai KR. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol., 2005, 23, 7697-702.
77. O'Brien, S.; Moore, J.O.; Boyd, T.E. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 20, 1114-20.
78. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Harris, D.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; Andreeff, M. Mechanisms of antileukemic activity of the novel bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res., 2008, 68, 3413-20.
79. Nguyen, M.; Marcellus, R.C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy, Madiraju, S.R.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R.W.; Beauparlant, P.; Shore, G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 19512-7
80. Pérez-Galán, P.; Roué, G.; López-Guerra, M.; Nguyen, M.; Villamor, N.; Montserrat, E.; Shore, G.C.; Campo, E.; Colomer, D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, 22, 1712-20.
81. O'Brien, S.M.; Claxton, D.F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M.J.; Viallet, J. Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 2009, 113, 299-305.
82. Huang, S.; Sinicrope FA. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res., 2008, 68, 2944-51.
83. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; Joseph, M.K.; Kitada, S.; Korsmeyer, S.J.; Kunzer, A.R, Letai, A.; Li, C.; Mitten, M.J.; Nettesheim, D.G. Ng, S.; Nimmer, P.M.; O'Connor, J.M.; Oleksijew, A.; Petros, A.M.; Reed, J.C.; Shen, W.; Tahir, S.K.; Thompson, C.B.; Tomaselli, K.J.; Wang, B.; Wendt, M.D.; Zhang, H.; Fesik, S.W.; Rosenberg, S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005, 435, 677-81.
84. Song, J.H.; Kandasamy, K.; Kraft, A.S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem., 2008, 283, 25003-13
85. Paoluzzi, L.; Gonen, M.; Bhagat, G.; Furman, R.R.; Gardner, J.R.; Scotto, L.; Gueorguiev, V.D.; Heaney, M.L.; Manova, K.; O'Connor, O.A. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, 112, 2906-16.
86. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: A potent and orally bioavailable bcl-2 family inhibitor. Cancer Res., 2008, 8, 3421-8.
87. Lock, R.; Carol, H.; Houghton, P.J.; Morton, C.L.; Kolb, E.A.; Gorlick, R.; Reynolds, C.P.; Maris, J.M.; Keir, S.T.; Wu, J.; Smith, M.A. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr. Blood Cancer, 2008, 50, 1181-9.
88. Paoluzzi, L.; Gonen, M.; Gardner. J.R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; Heaney, M.L.; O'Connor, O.A. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood, 2008, 111, 5350-8.
89. Kline, M.P.; Rajkumar, S.V.; Timm, M.M.; Kimlinger, T.K.; Haug, J.L.; Lust, J.A.; Greipp, P.R.; Kumar, S. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp. Hematol., 2008, 36, 568-76.
90. Wang, G.; Nikolovska-Coleska, Z.; Yang, C.Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P.P.; Abaan, H.O.; Tomita, Y.; Wang, S. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem., 2006, 49, 6139-42.
91. Wu, D. An overview of the clinical pharmacology and therapeutic potential of gossypol as a male contraceptive agent and in gynaecological disease. Drugs, 1989, 38, 333-41
92. Fährmann, M. Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system. Curr. Med. Chem., 2008, 15, 1175-91.
93. Christian, B.A.; Grever, M.R.; Byrd, J.C.; Lin, TS. Flavopiridol in the treatment of chronic lymphocytic leukemia. Curr. Opin. Oncol., 2007, 19, 573-8.
94. Kitada, S.; Zapata, J.M.; Andreeff, M.; Reed, J.C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 2000, 96, 393-7.
95. Billard, C.; Kern, C.; Tang, R.; Ajchenbaum-Cymbalista, F.; Kolb, J.P. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia, 2003, 17, 2435-43
96. Billard, C.; Menasria, F.; Quiney, C.; Faussat, A.M.; Kolb, J.P. Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent. Leuk. Res. 2008, 32, 755-60.
97. Flinn, IW.; Byrd, J.C.; Bartlett, N.; Kipps, T.; Gribben, J.; Thomas, D.; Larson, R.A.; Rai, K.; Petric, R.; Ramon-Suerez, J.; Gabrilove, J.; Grever, M.R. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity. Leuk. Res., 2005, 29, 1253-7.
98. Byrd, J.C.; Peterson, B.L.; Gabrilove, J.; Odenike, O.M.; Grever, M.R.; Rai, K.; Larson, R.A. Cancer and Leukemia Group B. Treatment of relapsed chronic lymphocytic leukemia by 72 hour continuous infusion or 1-hour bolus infusion of flavopiridol: Results from Cancer and Leukemia Group B study 19805. Clin Cancer Res., 2005, 11, 4176-81
99. Byrd, J.C.; Lin, T.S.; Dalton, J.T.; Wu, D.; Phelps, M.A.; Fischer, B.; Moran, M.; Blum, K.A.; Rovin, B.; Brooker-McEldowney, M.; Broering, S.; Schaaf, L.J, Johnson, A.J.; Lucas, D.M.; Heerema, N.A.; Lozanski, G.; Young, D.C.; Suarez, J.R.; Colevas, A.D.; Grever, M.R. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109, 399-404.
100. Mutter, R.; Wills, M. Chemistry and clinical biology of the bryostatins. Bioorg. Med. Chem., 2000, 8, 1841-60.
101. Jaggi, M.; Chauhan, S.C.; Du C, Balaji, K.C. Bryostatin 1 modulates beta- catenin subcellular localization and transcription activity through protein kinase D1 activation. Mol. Cancer Ther. 2008, 7, 2703-12.
102. Beck, F.W.; Eilender, D.S.; Dandashi, M.H.; Siddiq, F.; Snell, D.C.; Godmere, M.A.; Al-Katib, A.M.; Mohammad, R.M. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia. Int. J. Mol. Med., 2004, 1, 113-9.
103. Mohammad, R.M.; Katato, K.; Almatchy, V.P.; Wall, N.; Liu, K.Z.; Schultz, C.P.; Mantsch, H.H.; Varterasian, M.; al-Katib, A.M. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed 2-chlorodeoxyadenosine: Preclinical studies. Clin. Cancer Res., 1998, 4, 445-53.
104. Roberts, J.D.; Smith, M.R.; Feldman, E.J.; Cragg, L.; Millenson, M.M.; Roboz, G.J.; Honeycutt, C.; Thune, R.; Padavic-Shaller, K.; Carter, W.H.; Ramakrishnan, V.; Murgo, A.J.; Grant, S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin. Cancer Res., 2006, 12, 5809-16.
105. Li, F.; Grant, S.; Pettit, G.R.; McCrady, C.W. Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor. Blood, 1992, 80, 2495-502.
106. McCrady, C.W.; Li, F.; Pettit, G.R.; Grant, S. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/ interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1. Exp. Hematol. 1993, 21, 893-900.
107. Meijer, L.; Borgne, A.; Mulner, O.; Chong, J.P.; Blow, J.J.; Inagaki, N.; Inagaki, M.; Delcros, J.G.; Moulinoux, J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem., 1997, 243, 527-36.
108. Hahntow, I.N.; Schneller, F.; Oelsner, M.; Weick, K.; Ringshausen, I.; Fend, F.; Peschel, C.; Decker, T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia, 2004, 18, 747-55.
109. Benson, C.; White, J.; De Bono, J.; O'Donnell, A.; Raynaud, F.; Cruickshank, C.; McGrath, H.; Walton, M.; Workman, P.; Kaye, S.; Cassidy, J.; Gianella-Borradori, A.; Judson, I.; Twelves, C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer, 2007, 96, 29-37.
110. Alvi, AJ.; Austen, B.; Weston, V.J.; Fegan, C.; MacCallum, D.; Gianella-Borradori, A.; Lane, D.P.; Hubank, M.; Powell, J.E.; Wei, W.; Taylor, A.M.; Moss, P.A.; Stankovic, T.A. Novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood, 2005, 105, 4484-91.
111. McClue, S.J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P.M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, D. Lane DP. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer, 2002, 102, 463-8
112. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res., 2003, 36, 417-25.
113. Ma, S.; Rosen, S.T. Enzastaurin. Curr. Opin. Oncol., 2007, 19, 590-5.
114. Chen, Y.B.; LaCasce, A.S. Enzastaurin. Expert. Opin. Investig. Drugs, 2008, 17, 939-44.
115. Teicher, B.A.; Alvarez, E.; Menon, K.; Esterman, M.A.; Considine, E.; Shih, C.; Faul, M.M. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemother. Pharmacol., 2002, 49, 69-77.
116. Keyes, K.A.; Mann, L.; Sherman, M.; Galbreath, E.; Schirtzinger, L.; Ballard, D.; Chen, Y.F.; Iversen, P.; Teicher, B.A. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol., 2004, 53, 133-40.
117. Graff, J.R.; McNulty, A.M.; Hanna, K.R.; Konicek, B.W.; Lynch, R.L.; Bailey, S.N.; Banks, C.; Capen, A.; Goode, R.; Lewis, J.E.; Sams, L.; Huss, K.L.; Campbell, R.M.; Iversen, P.W.; Neubauer, B.L.; Brown, T.J.; Musib, L.; Geeganage, S.; Thornton, D. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res., 2005, 65, 7462-9.
118. Podar, K.; Raab, M.S.; Zhang, J.; McMillin, D.; Breitkreutz, I.; Tai, Y.T.; Lin BK.; Munshi, N.; Hideshima, T.; Chauhan, D.; Anderson, K.C. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood, 2007, 109, 1669-77.
119. Neri, A.; Marmiroli, S.; Tassone, P.; Lombardi, L.; Nobili, L.; Verdelli, D.; Civallero, M.; Cosenza, M.; Bertacchini, J.; Federico, M.; De Pol A.; Deliliers, GL.; Sacchi, S. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma, 2008, 49, 1374-83.
120. Moreau, A.S.; Jia, X.; Ngo, H.T.; Leleu, X.; O'Sullivan, G.; Alsayed, Y.; Leontovich, A.; Podar, K.; Kutok, J.; Daley, J.; Lazo-Kallanian, S.; Hatjiharissi, E.; Raab, M.S.; Xu, L.; Treon, S.P.; Hideshima, T.; Anderson, K.C.; Ghobrial, I.M. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood, 2007, 109, 4964-72.
121. Carducci, M.A.; Musib, L.; Kies, M.S.; Pili, R.; Truong, M.; Brahmer, J.R.; Cole, P.; Sullivan, R.; Riddle, J.; Schmidt, J.; Enas, N.; Sinha, V.; Thornton, D.E.; Herbst, RS. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol., 2006, 24, 4092-9.
122. Robertson, M.J.; Kahl, B.S.; Vose, J.M.; de Vos, S.; Laughlin, M.; Flynn, P.J.; Rowland, K.; Cruz, J.C.; Goldberg, S.L.; Musib, L.; Darstein, C.; Enas, N.; Kutok, J.L.; Aster, J.C.; Neuberg, D.; Savage, K.J.; LaCasce, A.; Thornton, D.; Slapak, C.A.; Shipp, M.A. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol., 2007, 25, 1741-6.
123. Morschhauser F, Seymour JF, Kluin-Nelemans HC, Grigg A, Wolf M, PfreundschuhM, Tilly H, Raemaekers J, van't Veer MB, Milpied N, Cartron G, Pezzutto A, Spencer A, Reyes F, Dreyling M. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol., 2008, 19, 247-53.
124. Lech-Marańda, E.; Robak, E.; Korycka, A.; Robak, T: Depsipep-tyde (FK 228) as a novel histone deacetylase inhibitor. Mini-Rev. Med. Chem., 2007, 7, 1062-69.
125. Piekarz, R.; Bates, S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr. Pharm. Des. 2004, 10, 2289-98.
126. Drummond, D.C.; Noble, C.O.; Kirpotin, D.B.; Guo, Z.; Scott, G.K.; Benz, C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol., 2004, 45, 495-528.
127. Gore, S.D.; Carducci, M.A. Modifying histones to tame cancer: Clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs, 2000, 9, 2923-34.
128. Gore, S.D.; Weng, L.J.; Zhai, S.; Figg, W.D.; Donehower, R.C.; Dover, G.J.; Grever, M.; Griffin, C.A.; Grochow, L.B.; Rowinsky, E.K.; Zabalena, Y.; Hawkins, A.L.; Burks, K.; Miller, C.B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res., 2001, 7, 2330-9.
129. Gore, S.D.; Weng, L.J.; Figg, W.D.; Zhai, S.; Donehower, R.C.; Dover, G.; Grever, M.R.; Griffin, C.; Grochow, L.B.; Hawkins, A.; Burks, K.; Zabelena, Y.; Miller, C.B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res., 2002, 8, 963-70.
130. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H.; Tanaka, A.; Komatsu, Y.; Nishino, N.; Yoshida, M.; Horinouchi, S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res., 2002, 62, 4916-21.
131. Thiagalingam, S.; Cheng, K.H.; Lee, H.J.; Mineva, N.; Thiagalingam, A.; Ponte, J.F Histone deacetylases: Unique players in shaping the epigenetic histone code. Ann. N. Y. Acad. Sci., 2003, 983, 84-100.
132. Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Ocologist, 2007, 12, 1247-1252.
133. Byrd, J.C.; Marcucci, G.; Parthun, M.R.; Xiao, J.J.; Klisovic, R.B.; Moran, M.; Lin, T.S.; Liu, S.; Sklenar, A.R.; Davis, M.E.; Lucas, D.M.; Fischer, B.; Shank, R.; Tejaswi, S.L.; Binkley, P.; Wright, J.; Chan, K.K.; Grever, M.R.A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 2005, 105, 959-967.
134. Nishioka, C.; Ikezoe, T.; Yang, J.; Komatsu, N.; Bandobashi, K.; Taniguchi, A.; Kuwayama, Y.; Togitani, K.; Koeffler, H.P, Taguchi H. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappa B. Leuk. Res., 2008, 32, 1382-92.
135. Grant, S.; Easley, C.; Kirkpatrick, P. Vorinostat. Nat. Rev. Drug Discov., 2007, 6, 21-22.
136. Olsen, E.A.; Kim, Y.H.; Kuzel, T.M.; Pacheco, T.R.; Foss, F.M.; Parker, S.; Frankel, S.R.; Chen, C.; Ricker, J.L.; Arduino, J.M.; Duvic, M. Phase IIb multicenter trial of vorinostat in patients with persistent progressive or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol., 2007, 25, 3109-15.
137. Costa, L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat. Rev. 2007, 33, 78-84.
138. Janus, A.; Robak, T.; Smolewski, P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell Mol. Biol. Lett., 2005, 10, 479-98.
139. Smolewski, P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin. Investig. Drugs, 2006, 15, 1201-27.
140. Faivre, S.; Kroemer, G.; Raymond, E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug. Discov., 2006, 5, 671-88.
141. Brown, E.J.; Albers, M.W.; Shin, T.B.; Ichikawa, K.; Keith, C.T.; Lane, W.S.; Schreiber, S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature, 1994, 369, 756-8.
142. Schmelzle, T.; Hall, M.N. TOR, a central controller of cell growth. Cell, 2000, 103, 253-62.
143. Panwalkar, A.; Verstovsek, S.; Giles, F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer, 2004, 100, 657-66.
144. Shaw, R.J.; Cantley, L.; Ras, P.I. (3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441, 424-30.
145. Chan, S. Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br. J. Cancer, 2004, 91, 1420-4.
146. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4, 988-1004.
147. Cohen. E.E.W. mTOR: The Mammalian target of replication. J. Clin. Oncol., 2008, 26, 348-349.
148. Shaw, R.J.; Cantley, L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441, 424-30.
149. Smolewski, P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs, 2006, 17, 487-94.
150. Douros, J.; Suffness. M. New antitumor substances of natural origin. Cancer Treat. Rev., 1981, 8, 63-87.
151. Yee, K.W.; Zeng, Z.; Konopleva, M.; Verstovsek, S.; Ravandim F.; Ferrajolim A.; Thomas, D.; Wierda, W.; Apostolidou, E.; Albitar, M.; O'Brien, S.; Andreeff, M.; Giles, F.J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2006, 12, 5165-73.
152. Dunn, C.; Croom KF.verolimus: A review of its use in renal and cardiac transplantation. Drugs, 2006, 66, 547-70.
153. Kirchner, G.I.; Meier-Wiedenbach, I.; Manns, M.P. Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet., 2004, 43, 83-95.
154. Haritunians, T.; Mori, A.; O'Kelly, J.; Luong, Q.T.; Giles, F.J.; Koeffler, H.P. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia, 2007, 21, 333-9.
155. Decker, T.; Sandherr, M.; Goetze, K.; Oelsner, M.; Ringshausen, I.; Peschel, C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann. Hematol., 2009, 88, 221-7.
156. Mita, M.M.; Mita, A.C.; Chu, Q.S.; Rowinsky, E.K.; Fetterly, G.J.; Goldston, M.; Patnaik, A.; Mathews, L.; Ricart, A.D.; Mays, T.; Knowles, H.; Rivera, V.M.; Kreisberg, J.; Bedrosian, C.L.; Tolcher, A.W. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus(AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks topatients with advanced malignancies. J. Clin. Oncol., 2008, 26, 361-7.
157. Rizzieri, D.A.; Feldman, E.; Dipersio, J.F.; Gabrail, N.; Stock, W.; Strair, R.; Rivera, V.M.; Albitar, M.; Bedrosian, C.L.; Giles, F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res., 2008, 14, 2756-62.
158. Witzig, T.E.; Geyer, S.M.; Ghobrial, I.; Inwards, D.J.; Fonseca, R.; Kurtin, P.; Ansell, S.M.; Luyun, R.; Flynn, P.J.; Morton, R.F.; Dakhil, S.R.; Gross, H.; Kaufmann, S.H. Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol., 2005, 23, 5347-56.
159. Ansell, S.M.; Inwards, D.J.; Rowland, K.M Jr.; Flynn, P.J.; Morton. R.F.; Moore, D.F. Jr.; Kaufmann, S.H.; Ghobrial, I.; Kurtin, P.J.; Maurer, M.; Allmer, C.; Witzig, T.E. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer, 2008, 113, 508-14
160. VINK, J..; Cloos, J.; Kaspers, G.J. Proteasome inhibition as novel treatment strategy in leukaemia. Br. J. Haematol., 2006, 134, 253-62.
161. Mitsiades, C.S.; Mitsiades, N.; Hideshima, T.; Richardson, P.G.; Anderson, K.C. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr. Drug Targets, 2006, 7, 1341-7.
162. Hayden, P.J.; Mitsiades, C.S.; Anderson, K.C.; Richardson, P.G. Novel therapies in myeloma. Curr. Opin. Hematol., 2007, 14, 609-15.
163. Richardson, P.G.; Mitsiades, C.; Schlossman, R.; Ghobrial, I.; Hideshima, T.; Munshi, N.; Anderson, K.C. Bortezomib in the front-line treatment of multiple myeloma. Expert. Rev. Anticancer Ther., 2008, 8, 1053-72.
164. Liu, F.T.; Agrawal, S.G.; Gribben, J.G.; Ye, H.; Du, M.Q.; Newland, A.C.; Jia, L. Bortezomib blocks Bax degradation in malignant B cells during treatment with Trial. Blood, 2008, 111, 2797-805.
165. Mitsiades, C.S.; Mitsiades, N.; Hideshima, T.; Richardson, P.G.; Anderson, K.C. Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert. Rev. Anticancer Ther., 2005, 5, 465-76.
166. Mateos, M.V.; San Miguel, J.F. Bortezomib in multiple myeloma. Best Pract. Res. Clin. Haematol., 2007, 20, 701-15
167. Adams, J. Proteasome inhibitors as new anticancer drugs. Curr. Opin. Oncol., 2002, 14, 628-34.
168. Goy, A.; Younes, A.; McLaughlin, P.; Pro, B.; Romaguera, J.E.; Hagemeister, F.; Fayad, L.; Dang, N.H.; Samaniego, F.; Wang, M.; Broglio, K.; Samuels, B.; Gilles, F.; Sarris, A.H.; Hart, S.; Trehu, E.; Schenkein, D.; Cabanillas, F.; Rodriguez, A.M. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 2005, 23, 667-75.
169. O'Connor, O.A.; Wright, J.; Moskowitz, C.; Muzzy, J.; MacGregor Cortelli, B.; Stubblefield, M.; Straus, D.; Portlock, C.; Hamlin, P.; Choi, E.; Dumetrescu, O.; Esseltine, D.; Trehu, E.; Adams, J.; Schenkein, D.; Zelenetz, A.D. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol., 2005, 23, 676-84.
170. Belch, A.; Kouroukis, C.T.; Crump, M.; Sehn, L.; Gascoyne, R.D.; Klasa, R.; Powers, J.; Wright, J.; Eisenhauer, E.A. A phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann. Oncol., 2007, 18, 116-21.
171. Faderl, S.; Rai, K.; Gribben, J.; Byrd, J.C.; Flin, I.W.; O'Brien, S.; Sheng, S.; Esseltine, D.L.; Keating, M.J. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine - refractory B-cell chronic lymphocytic leukemia. Cancer, 2006, 107, 916-24.
172. Smolewski, P.; Duechler, M, Linke, A.; Cebula, B.; Grzybowska-Izydorczyk, O.; Shehata, M.; Robak, T. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk. Res., 2006, 30, 1521-9.
173. Duechler, M.; Linke, A.; Cebula, B.; Shehata, M.; Schwarzmeier, J.D.; Robak, T.; Smolewski, P. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur. J. Haematol., 2005, 74, 407-17.
174. Dai, Y.; Chen, S.; Kramer, L.B.; Funk, V.L.; Dent, P.; Grant, S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin. Cancer Res., 2008, 14, 549-58.
175. Ruiz, S.; Krupnik, Y.; Keating, M.; Chandra, J.; Palladino, M.; McConkey, D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol. Cancer Ther., 2006, 5, 1836-43.
176. Jabbour, E.; Cortes, J.E.; Ghanem, H.; O'Brien, S.; Kantarjian, H.M. Targeted therapy in chronic myeloid leukemia. Expert. Rev. Anticancer Ther., 2008, 8, 99-110.
177. Gora-Tybor, J.; Robak, T. Targeted drugs in chrinic myeloid leukemia. Curr. Med. Chem., 2008, 15, 3036-51.
178. Lin, K.; Glenn, M.A.; Harris, R.J.; Duckworth, A.D.; Dennett, S.; Cawley, J.C.; Zuzel, M.; Slupsky, J.R. c-Abl expression in chronic lymphocytic leukemia cells: Clinical and therapeutic implications. Cancer Res., 2006, 66, 7801-9.
179. Aloyz, R.; Grzywacz, K.; Xu, Z.Y.; Loignon, M.; Alaoui-Jamali, M.A.; Panasci, L. Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia, 2004, 18, 409-14.
180. Veldurthy, A.; Patz, M.; Hagist, S.; Pallasch, C.P.; Wendtner, C.M.; Hallek, M.; Krause, G. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood, 2008, 112, 1443-52.
181. Amrein, L.; Hernandez, T.A.; Ferrario, C.; Johnston, J.; Gibson, S.B.; Panasci, L.; Aloyz, R. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br. J. Haematol., 2008, 143, 698-706.
182. Contri, A.; Brunati, A.M.; Trentin, L.; Cabrelle, A.; Miorin, M.; Cesaro, L.; Pinna, L.A.; Zambello, R.; Semenzato, G.; Donella-Deana, A. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest., 2005, 115, 369-78.
183. Lee, M.; Kim, J.Y.; Koh, W.S. Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia. J. Cell Biochem., 2004, 93, 629-38.
184. Pellagatti, A.; Jädersten, M.; Forsblom, A.M.; Cattan, H.; Christensson, B.; Emanuelsson, E.K.; Merup, M.; Nilsson, L.; Samuelsson, J.; Sander, B.; Wainscoat, J.S.; Boultwood, J.; Hellström-Lindberg, E. Lenalidomide inhibits the malignant clone and upregulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 11406-11
185. Lapalombella, R.; Gowda, A.; Joshi, T.; Mehter, N.; Cheney, C.; Lehman, A.; Chen, C.S.; Johnson, A.J.; Caligiuri, M.A.; Tridandapani, S.; Muthusamy, N.; Byrd, J.C. The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia. Br. J. Haematol., 2009, 144, 848-55.
186. Chanan-Khan, A.; Porter, C.W. Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol., 2006, 7, 480-488.
187. Raje, N.; Anderson, K.C. Thalidomide and immunomodulatory drugs as cancer therapy. Curr. Opin. Oncol., 2002, 14, 635-40.
188. Vallet, S.; Palumbo, A.; Raje, N.; Boccadoro, M.; Anderson, K.C. Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk. Lymphoma, 2008, 49, 1238-45
189. Lapalombella, R.; Yu, B.; Triantafillou, G.; Liu, Q.; Butchar, J.P.; Lozanski, G.; Ramanunni, A.; Smith, L.L.; Blum, W.; Andritsos, L.; Wang, D.S.; Lehman, A.; Chen, C.S.; Johnson, A.J.; Marcucci, G.; Lee, R.J.; Lee, L.; Tridandapani, S.; Muthusamy, N.; Byrd, J.C. Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood, 2008, 112, 5180-9.
190. Gupta, D.; Treon, S.P.; Shima, Y.; Hideshima, T.; Podar, K.; Tai, Y.T.; Lin, B.; Lentzsch, S.; Davies, F.E.; Chauhan, D.; Schlossman, R.L.; Richardson, P.; Ralph, P.; Wu, L.; Payvandi, F.; Muller, G.; Stirling, D.I.; Anderson, K.C. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 2001, 15, 1950-61.
191. Chanan-Khan, A.; Miller, K.C.; Takeshita, K.; Koryzna, A.; Donohue, K.; Bernstein, Z.P.; Mohr, A.; Klippenstein, D.; Wallace, P.; Zeldis, J.B.; Berger, C.; Czuczman, M.S. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood, 2005, 106, 3348-52.
192. Laurenti, L.; Piccioni, P.; Tarnani, M.; De Padua, L.; Garzia, M.; Efremov, D.G.; Piccirillo, N.; Chiusolo, P.; Sica, S.; Leone, G. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia. Leuk. Res., 2007, 31, 253-6.
193. Morotti, A.; Ciloni, D.; Parvis, G.; Guerrasio, A.; Saglio, G. Thalidomide - induced partial stable remission in a case of refractory progressive B cell chronic lymphoid leukemia. Leuk. Res., 2007, 32, 506-7.
194. Chanan-Khan, A.; Miller, K.C.; Musial, L.; Lawrence, D.; Padmanabhan, S.; Takeshita, K.; Porter, C.W.; Goodrich, D.W.; Bernstein, Z.P.; Wallace, P.; Spaner, D.; Mohr, A.; Byrne, C.; Hernandez-Ilizaliturri. F.; Chrystal. C.; Starostik, P.; Czuczman, M.S. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J. Clin. Oncol., 2006, 24, 5343-9.
195. Ferrajoli, A.; Lee, B.N.; Schlette, E.J.; O'Brien, S.M.; Gao, H.; Wen, S.; Wierda, W.G.; Estrov, Z.; Faderl, S.; Cohen, E.N.; Li, C.; Reuben, J.M.; Keating, M.J. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood, 2008, 111, 52-61.
196. Andritsos, L.A.; Johnson, A.J.; Lozanski, G.; Blum, W.; Kefauver, C.; Awan, F.; Smith, L.L.; Lapalombella, R.; May, S.E.; Raymond, C.A.; Wang, D.S.; Knight, R.D.; Ruppert, A.S.; Lehman, A.; Jarjoura, D.; Chen, C.S.; Byrd, J.C. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2008, 26, 2519-25.
197. Lin, T. Lenalidomide: What is the right dose in CLL. Blood, 2008, 111, 52-68.
198. Urlich, C.M.; Bigler, J.; Potter, J.D. Non-steroidal antiinflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat. Rev. Cancer, 2006, 6, 130-40.
199. De Groot, D.J.A.; de Vries, E.G.E.;Groen, H.J.M.; de Jong,S. Nonsteroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit. Rev. Oncol. Hematol., 2007, 61, 52-9.
200. Robak, P.; Smolewski, P.; Robak, T. The role of noonsteroidal antiinflamatory drugs in the risk of development and treatment of hematologic malignancies. Leuk. Lymphoma, 2008, 49, 1452-62.
201. Yasui, H.; Hideshima, T.; Anderson, K.C. Non-steroidal antiinflammatory drug therapy for chronic lymphocytic leukemia. Leuk. Lymphoma, 2006, 41, 2445-46.
202. Demerson, C.A.; Humber, L.G.; Abraham, N.A.; Schilling, G.; Martel, R.R.; Pace-Asciak, C. Resolution of etadolac and anti-inflammatory and prostaglandin synthetase inhibiting properties of enantiomers. J. Med. Chem., 1983, 26, 1778-80.
203. Sheith, K.J.; Brocks, D.R. Pharmacokinetic optimisation of the treatment of osteorthritis. Clin. Pharmacokinet, 1999, 26, 233-2.
204. Nardella, F.A.; LeFevre, J.A. Enchanced clearance of leukemic lymphocytes in B-cell chronic lymphocytic leukemia with etodolac. Blood, 2002, 99, 2625-26.
205. Lu, D.; Zhao, Y.; Tawatao, R.; Cottam, H.B.; Sen, M.; Leoni, L.M.; Kipps, T.J.; Corr, M.; Carson, D.A. Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 3118-23.
206. Feng, R.; Lentzsch, S. Treatment of multiple myeloma with SDX-308. Drug News Perspect., 2007, 20, 431-435.
207. Yasui, H.; Hideshima, T.; Ikeda, H.; Ocio, E.M.; Kiziltepe, T.; Vallet, S.; Okawa, Y.; Neri, P.; Sukhdeo, K.; Podar, K.; Chauhan, D.; Richardson, P.G.; Raje, N.; Carrasco, D.R.; Anderson, K.C. Novel etodolac analog SDX-308 (CEP-18082 ) induces cytotooxicity in multiple myeloma cells associated with inhibition of β-catenin/TCI pathway. Leukemia, 2007, 21, 535-40.
208. Lindhagen, E.; Nissle, S.; Leoni, L.; Elliott, G.; Chao, Q.; Larsson, K.; Aleskag, A. E-etodolac (SDX-101) and the related indole pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukemia cells. Cancer Chemother. Pharmacol., 2007, 60, 545-3.
209. Feng, R.; Anderson, G.; Xiao, G.; Elliott, G.; Leoni, L.; Mapara, M.Y.; Roodman, G.D.; Lentzsch, S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood, 2007, 109, 2130-38.
210. Robak, P.; Linke, A.; Cebula, B.; Robak, T.; Smolewski, P. Cytotoxic effects of R-etadolac (SDX 101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk. Lymphoma, 2006, 47, 2625-34
211. Robak, T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma, 2004, 45, 205-19.
212. Robak T. Novel monoclonal antibodies for chronic lymphocytic leukemia. Curr. Cancer Drug Targets, 2008, 8, 156-171.
213. Robak, T. Ofatumumab, a human mAb for lymphoid malignancies and autoimmune disorders. Curr. Opin. Mol. Ther., 2008, 10, 294-309.
214. Coiffier, B.; Lepretre, S.; Pedersen, L.M.; Gadeberg, O.; Fredriksen, H.; van Oers, M.H.; Wooldridge, J.; Kloczko, J.; Holowiecki, J.; Hellmann, A.; Walewski, J.; Flensburg M, Petersen J, Robak T. Safety and efficacy ofofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase I-II study. Blood, 2008, 111, 1094-100.
215. Carnahan, J.; Stein, R.; Qu, Z.; Hess, K.; Cesano, A.; Hansen, H.J.; Goldenberg, D.M. Epratunuzumab, a CD22-targetingrecombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol., 2007, 44, 1331-41.
216. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev. Anticancer Ther., 2006, 6, 1341-1353.
217. Leonard, J.P.; Goldenberg, D.M. Preclinical and clinical evaluation of epratuzumab(anti-CD22 IgG) in B-cell malignancies. Oncogene 2007, 26, 3704-13.
218. Leonard, J.P.; Coleman, M.; Ketas, J.C.; Chadburn, A.; Ely, S.; Furman, R.R.; Wegener, W.A.; Hansen, H.J.; Ziccardi, H.; Eschenberg, M.; Gayko, U.; Cesano, A.; Goldenberg, D.M. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J. Clin. Oncol., 2003, 21, 3051-59.
219. Pathan, N.I.; Chu, P.; Hariharan, K.; Cheney, C.; Molina, A.; Byrd, J. Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood, 2008, 111, 1594-602.
220. Kim, Y.H.; Duvic, M.; Obitz, E.; Gniadecki, R.; Iversen, L.; Osterborg, A.; Whittaker, S.; Illidge, T.M.; Schwarz, T.; Kaufmann, R.; Cooper, K.; Knudsen, K.M.; Lisby, S.; Baadsgaard, O.; Knox, S.J. Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood, 2007, 109, 4655-62.
221. Kreitman, R.J.; Pastan, I: Immunotoxins in the treatment of hematologic malignancies. Curr. Drug Targets, 2006, 7, 1301-11.
222. Olsen, E.; Duvic, M.; Frankel, A.; Kim, Y.; Martin, A.; Vonderheid, E.; Jegasothy, B.; Wood, G, Gordon, M.; Heald, P.; Oseroff, A.; Pinter-Brown, L.; Bowen, G.; Kuzel, T.; Fivenson, D.; Foss, F.; Glode, M.; Molina, A.; Knobler, E.; Stewart, S.; Cooper, K.; Stevens, S.; Craig, F.; Reuben, J.; Bacha, P. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol., 2001, 19, 376-88.
223. Kreitman, R.J.; Wilson, W.H.; Bergeron, K.; Raggio, M.; Stetler-Stevenson, M.; FitzGerald, D.J.; Pastan. I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy -resistant hairy - cell leukemia. N. Engl. J. Med., 2001, 345, 241-7.
224. Salvatore, G.; Beers, R.; Margulies, I.; Kreitman, R.J, Pastan I. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res., 2002, 8, 995-1002.
225. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv) PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol., 2005, 23, 6719-29.
226. Bang, S.; Nagata, S.; Onda, M.; Kreitman, R.J.; Pastan, I: HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin. Cancer Res., 2005, 11, 1545-50.
227. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Giardina S, Waldmann TA, Pastan I. Phase I trial of recombinant immunotoxin anti - Tac (Fv) - PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., 2000, 18, 1622-36
228. Kreitman, R.J.; Pastan, I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol. Oncol. Clin. North Am., 2006, 20, 1137-51.
229. Morgan, S.J.; Seymour, J.F.; Prince, H.M.; Westerman, D.A.; Wolf. M/M. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin. Cancer Res., 2004, 10, 3572-5.
230. Olsen, E.; Duvic, M.; Frankel, A.; Kim, Y.; Martin, A.; Vonderheid, E.; Jegasothy, B.; Wood, G.; Gordon, M.; Heald, P.; Oseroff, A.; Pinter-Brown, L.; Bowen, G.; Kuzel, T.; Fivenson, D.; Foss, F.; Glode, M.; Molina, A.; Knobler, E.; Stewart, S.; Cooper, K.; Stevens, S.; Craig, F.; Reuben, J.; Bacha, P.; Nichols, J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol., 2001, 19, 376-8